

586 New class of mTOR inhibitor stabilizes intermediate filament networks in severe epidermolysis bullosa simplex keratinocytes

K. McGuire • A. McCormick • D. Huey

DOI: <https://doi.org/10.1016/j.jid.2022.05.595>  Check for updates

Article info
Related Articles

Epidermolysis Bullosa Simplex (EBS) is a rare genodermatosis caused by mutations in either KRT5 or KRT14. Severe EBS (i.e., EBS Dowling-Meara) is characterized by extremely fragile skin with frequent and severe herpetiform blistering. Genetic mutations cause poor keratin 5/14 dimerization resulting in mechanically weakened intermediate filament (IF) networks that collapse into intracellular aggregates upon stress (e.g., scratching, UV). Enhanced cellular removal and degradation of mutant keratins through stimulation of autophagy and the UPS system has the potential to strengthen the IF networks, reducing blistering and erosions. Previously, UPS cochaperones (e.g., 4-phenylbuterate) were shown to decreased keratin aggregation but also decreased keratinocyte adhesion and migration. The purpose of this research was to evaluate if BM-3103, (4-Hydroxy 4'-methoxytolan), a known wound healing promoter, anti-inflammatory, and autophagy inducer, could remove mutant keratins/aggregates thereby strengthening the IF network without adversely affecting cell survival, adhesion, or migration. Assays tested on patient derived EBS keratinocytes included: (1) Assessment of cytotoxicity, adhesion, and migration effects of BM-3103 using MTT, LDH, and scratch assays. (2) Autophagy induction (LC3-II conversion) and keratin aggregation (heat stress assay). There were no signs of cytotoxicity, loss of cell adhesion or slowed migration. Cells were exposed to escalating concentrations of BM-3103 for 24 hrs then heat shocked (43°C for 30min) generating an abundance of aggregates visualized by immunofluorescent microscopy. Untreated keratinocytes displayed keratin aggregate formation in 72% of KRT5 and 87% of KRT14 mutant cells. Treatment with BM-3103 reduced the incidence of keratin aggregates to 16% (p<0.01) of KRT5 and 24% (p<0.01) KRT14 mutant cells. BM-3103 is the first compound identified that is capable of stabilizing IF networks in keratinocytes from severe EBS patients. A clinical trial is ongoing to assess if BM-3103, can heal blistering areas and strengthen EBS patient skin.

Article info

Identification

DOI: <https://doi.org/10.1016/j.jid.2022.05.595>

Copyright

© 2022 Published by Elsevier Inc.

ScienceDirect

[Access this article on ScienceDirect](#)

Related Articles

ADVERTISEMENT

ISID 2023
10-13 May
Tokyo, Japan

LATE-BREAKING ABSTRACTS

DEADLINE 31 MARCH



Home	Contact	Submit a Manuscript	Psoriasis	Join ESDR
ARTICLES & ISSUES	Permissions	Why Publish in JID?	Resources for Clinical Research in the JID	Awards
Articles In Press	REVIEWERS	COLLECTIONS	NEWS	Events
Current Issue	Information for Reviewers	Atopic Dermatitis	Society/Journal News	Media
List of Issues	Reviewer Login	Cover Gallery	Advertisers	Education
Meeting Abstracts	JOURNAL INFO	Itch	SID	JAAD / JID Junction - NEW!
Supplements	About the Journal	JAAD / JID Junction	SID Member Activation	COMPANION TITLES
AUTHORS	About Open Access	Landmarks in Cutaneous Biology	SID Website	Journal of Investigative Dermatology Symposium Proceedings
About Open Access	Contact the Editorial Office	Melanoma	Join SID	JID Innovations
Submit a Manuscript	Editorial Board	Methods and Techniques for Skin Research	Annual Meeting	FOLLOW US
Welcome, Authors!	Abstracting/Indexing	Montagna Symposium on the Biology of Skin	Academic Industry Partnership	Facebook
Information for Authors	Access Instructions	Pemphigus & Pemphigoid	ESDR	Twitter
Information for Authors - PDF Download	New Content Alerts	Progress in Translational Research	ESDR Website	

We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the [Cookie settings | Your Privacy Choices](#) for this site.

Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.

[Privacy Policy](#) [Terms and Conditions](#) [Accessibility](#) [Help & Contact](#)

